Skip to content
دالستراپیب

Structure via PubChem · Public domain (PubChem)

EntityQ5210285· pop 6· linked from 91 articles

دالستراپیب

Sign in to save

Also known as Dalcetrapib

Dalcetrapib (INN, development code JTT-705) is a CETP inhibitor which was originally being developed by F. Hoffmann–La Roche until May 2012. DalCor Pharmaceuticals licensed dalcetrapib as a potential pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights into the development program, dalcetrapib is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome (ACS) and deliver superior cardiovascular outcome in a specific genetic subset of patients. A companion diagnostic test, developed

Chemical data

Formula
C23H35NO2S
Molecular weight
389.6 g/mol
IUPAC name
S-[2-[[1-(2-ethylbutyl)cyclohexanecarbonyl]amino]phenyl] 2-methylpropanethioate
SMILES
CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
InChIKey
YZQLWPMZQVHJED-UHFFFAOYSA-N
XLogP
7.1
Polar surface area
71.5 Ų
H-bond donors
1
H-bond acceptors
3
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Phase 3
Molecule type
Small molecule
Indications
cardiovascular disease, coronary artery disease, acute coronary syndrome, peripheral arterial disease

via ChEMBL · EBI

Wikidata facts

Mass
389.239
Show 3 more facts
chemical formula
C₂₃H₃₅NO₂S
canonical SMILES
CCC(CC)CC1(CCCCC1)C(=O)NC2=CC=CC=C2SC(=O)C(C)C
Commons category
Dalcetrapib
Sources (2)

via Wikidata · CC0

Available in 5 languages

via Wikidata sitelinks · CC0